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HCT is a common treatment for patients with high risk or
relapsed AML or ALL, although speciﬁc late effects in AML or
ALL survivors after HCT have not been well described. The
BMT-SS is a retrospective cohort study in which participants
completed a 255 item questionnaire on late effects occurring
after HCT. Eligible subjects received HCT between 1974-1998,
were 18 years or older at the time of interview and had survived
for 2 yrs after HCT. A random sample of 319 siblings of study
participants was recruited for comparison. The study included
253 survivors with AML and 100 with ALL. Mean age at HCT
was 32yr AML/22yr ALL (1.7-63yr), and the mean age at
interview was 41yr AML/34yr ALL (18-67yr), and 44yr (19-
79yr) for siblings. Subjects survived a mean of 10yr (2-25yr)
after HCT. Donor source was related (57% AML, 75% ALL),
autologous (35% AML, 18% ALL) or unrelated (8% AML, 7%
ALL); 82% from marrow, 17% from peripheral blood /-
marrow, and 0.8% cord blood. 82% of AML and 100% of ALL
subjects received TBI. The frequencies of late effects did not
differ between ALL and AML survivors. Compared to siblings,
survivors had a signiﬁcantly higher frequency of diabetes (DM,
9% vs 3%, p0.001), hypothyroidism (22% vs 7%, p0.001),
osteoporosis (9% vs 2%, p0.001), exercise induced shortness
of breath (EISB, 7% vs 2%, p0.006, neurosensory impair-
ments (30% vs 20%, p0.001), and problems with balance,
tremor or weakness (14% vs 5%, p0.001). Survivors also
reported signiﬁcantly higher frequency of requiring assistance
with activities of daily living, and having their health status
prevent school or work attendance. In multivariable analysis, the
risk of these outcomes did not differ by diagnosis. Survivors
after allogeneic HCT had higher odds of DM (odds ratio [OR]
3.92, 95% conﬁdence interval [CI] 1.09-14.01), osteoporosis
(OR 3.1, 95% CI 1.02-9.43), cardiopulmonary impairments
(OR 1.93, 95% CI 1.1-3.38), and abnormal sense of touch (OR
2.55, 95% CI 1.19-5.45) and were also more likely to have
difﬁculties with routine activities (OR 4.63, 95% CI 1.30-
16.54), and to report their overall health as fair or poor (OR
2.15, 95% CI 1.09-4.24). Those with a history of chronic
GVHD had signiﬁcantly higher odds of having EISB, neuro-
sensory impairments, and inability to attend school or work due
to their health. Ongoing surveillance for these late effects and
appropriate interventions are required to improve the health
status of ALL and AML survivors after HCT.
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Background
Although Hematopoietic Stem Cell Transplantation (HCT)
has the potential to increase survival for patients with many
diseases, particularly hematologic cancers, it is a complex and
costly procedure with substantial risk of morbidity and mortal-
ity. Increasing numbers of uninsured and underinsured persons
and health care marketplace competition raise concerns about
patients’ access to HCT in the United States. Many studies
demonstrate that African-Americans are more likely to be diag-
nosed at advanced stages of cancer and are less likely to receive
optimal care for cancer than Caucasians and that women are less
likely to receive some aggressive interventions than men. In this
study, we addressed the question of whether African-Americans
and women are would be less likely to receive HCT for hema-
tologic malignancy.
Methods
We estimated the annual incidence of leukemia, lymphoma
and multiple myeloma for African-Americans, Caucasians, men
and women under the age of 70 years in the U.S. using the
SEER Cancer Registry and U.S. Census reports. We estimated
the annual incidence of autologous, HLA-identical sibling and
unrelated HCT performed in these groups in the U.S. using
CIBMTR registration data for 1997 to 2002. Logistic regression
was used to calculate the age-adjusted odds ratio of receiving
HCT in groups deﬁned by race, gender and disease.
Results
The overall likelihood (or odds) of undergoing HCT for the
diseases considered was higher for Caucasians than for African-
Americans [OR1.40(1.34-1.46)]. This difference in likelihood
persisted for each type of HCT: autologous [OR1.24(1.19-
1.30)], HLA identical sibling [OR1.59(1.46-1.74)], and unre-
lated donor [OR2.02(1.75-2.33)]. Men were somewhat more
likely to receive HCT than women [OR1.07(1.05-1.1)]; how-
ever, this difference pertained only to autologous transplanta-
tion [OR1.1(1.06-1.13)]. The likelihoods of HLA identical
sibling [OR1.05(0.99-1.10)] and unrelated donor HCT
[OR0.94(0.88-1.01)] did not differ signiﬁcantly by gender.
Conclusions
Utilization of HCT for leukemia, lymphoma and multiple my-
eloma varies by race, with Caucasians more likely to receive HCT
than African-Americans. Lower HCT rates for African-Americans
were seen for both autologous and allogeneic HCT, indicating that
donor availability cannot fully explain the differences. Women
with lymphoma and multiple myeloma are also less likely than men
to receive autologous HCT for reasons unexplained by age or
disease status.
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Background: HCT-CI provided valid scoring of pretrans-
plant comorbidities that predicted non-relapse mortality and
survival for patients (pts) undergoing allogeniec HCT. It is
more sensitive and greater survival predictor than Charlson
Comorbidity Index (CCI). (Ref: M. Sorror et al, Blood Oct/05,
Vol 106). Objectives: To evaluate the predictive value of
HCT-CI and CCI for morbidity risk assessment in pts with
lymphoma undergoing AHCT. Morbidity was measured by the
duration of hospitalization (DOH) and the incidence of Hospi-
tal Re-Admission within 100 days post-AHCT (HRA-100).
Methods: We included pts with history of Hodgkin or non-
Hodgkin lymphoma (HL or NHL) who underwent AHCT in
our institution between 01/98 and 05/06. Since the prevalence
of comorbidities is less before the age of 40, only pts above this
age were included. Pts were given scores based on the HCT-CI
and CCI (table). Prior solid tumor comorbidity was excluded.
Results: 80 pts met the inclusion criteria , 74 had NHL and 6
had HL. 61 pts were male. Median age was 56 years (42-76).
Median DOH was 21 days (12-36). Median HCT-CI was 1: 37
% of pts had score 0, 26% had score 1, and 37 % had scores 2
to 7. Median CCI was 1: 46% of pts had score 0, 31% had score
1, and 23% had scores 2 to 3. 16 pts (20%) required HRA-100.
After adjustment for age at transplantation and type of condi-
tioning regimens, HCT-CI was signiﬁcantly correlated with the
DOH (p0.027, HR: 0.86), whereas the CCI was not (p 0.06,
HR: 0.79). Both HCT-CI and CCI were signiﬁcant predictors
for HRA-100 (p0.009, OR: 1.51; p 0.017, OR: 2.08, respec-
tively). Conclusion: HCT-CI predicted the morbidity risk after
AHCT for pts with lymphoma. Both HCT-CI and CCI were
strong predictors for the risk of HRA-100. HCT-CI is more
valid and reliable than CCI in predicting the DOH. HCT-CI
can serve as important tool for both the transplant administrator
when planning for resources allocation, and for patients during
pre-transplant evaluation and counseling.
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